Physiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case study
Johanna Eriksson, Marylore Chenel, Stephen Robinson(Intel (United States)), Jean‐Yves Gillon(Drugs for Neglected Diseases Initiative), Vijay Satam(Drugs for Neglected Diseases Initiative India), Vishal Goyal(Chandigarh University), Henri Caplain(Drugs for Neglected Diseases Initiative), Justine Jelagat Odionyi, Isabela Ribeiro(Drugs for Neglected Diseases Initiative)
Cited by 0
Related Papers
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
|Blood|2000|502
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
|Clinical Microbiology Reviews|2018|218
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
|PLoS neglected tropical diseases|2017|78
Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis
|BMC Public Health|2017|72